SOLID FORMS OF A CDK4 INHIBITOR
This invention relates to crystalline and amorphous forms of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, to pharmaceutical compositions comprising such solid forms, and to use of such solid for...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French |
Published |
24.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This invention relates to crystalline and amorphous forms of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.
Cette invention concerne des formes cristallines et amorphes de 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-didésoxy-D-thréo-pentitol, des compositions pharmaceutiques comprenant de telles formes solides, et l'utilisation de telles formes solides et de telles compositions pharmaceutiques pour le traitement du cancer. |
---|---|
Bibliography: | Application Number: WO2021IB58320 |